Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202

被引：0
|
作者：
Swiecicki, Paul
Yilmaz, Emrullah
Rosenberg, Ari J.
Fujisawa, Takao
Bruce, Justine Yang
Meng, Changting
Wozniak, Michele
Wang, Lu
Gorla, Seema Rao
Geiger, Jessica Lyn
机构：
[1] Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI USA
[2] Cleveland Clin, Cleveland, OH USA
[3] Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL USA
[4] Natl Canc Ctr East Hosp, Dept Head & Neck Med Oncol, Translat Res Support Off, Chiba, Japan
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[6] Seagen Inc, Bothell, WA USA
[7] Astellas Pharma US Inc, Northbrook, IL USA
[8] Astellas Pharma Inc, Northbrook, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6017
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
    Rosenberg, J. E.
    Milowsky, M.
    Ramamurthy, C.
    Mar, N.
    Mckay, R. R.
    Friedlander, T.
    Ferrario, C.
    Bracarda, S.
    George, S.
    Moon, H.
    Geynisman, D.
    Petrylak, D. P.
    Borchiellini, D.
    Burgess, E. F.
    Rey, J. P. Maroto
    Carret, A-S.
    Yu, Y.
    Guseva, M. V.
    Moreno, B. Homet
    O'Donnell, P. H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1441 - S1441
  • [32] EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
    O'Donnell, P.
    Galsky, M. D.
    Rosenberg, J. E.
    Petrylak, D. P.
    Balar, A. V.
    McGregor, B. A.
    Heath, E.
    Yu, E. Y.
    Quinn, D. I.
    Hahn, N. M.
    Campbell, M.
    Liang, S-Y.
    Steinberg, J.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S579 - S580
  • [33] Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
    O'Donnell, Peter H.
    Milowsky, Matthew I.
    Petrylak, Daniel P.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Mar, Nataliya
    Moon, Helen H.
    Friedlander, Terence W.
    McKay, Rana R.
    Bilen, Mehmet A.
    Srinivas, Sandy
    Burgess, Earle F.
    Ramamurthy, Chethan
    George, Saby
    Geynisman, Daniel M.
    Bracarda, Sergio
    Borchiellini, Delphine
    Geoffrois, Lionnel
    Rey, Jose Pablo Maroto
    Ferrario, Christiano
    Carret, Anne-Sophie
    Yu, Yao
    Guseva, Maria
    Moreno, Blanca Homet
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4107 - +
  • [34] Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study
    Nizam, A.
    Zhang, L.
    Jindal, T.
    Nguyen, C. B.
    Alhalabi, O.
    Basu, A.
    Evans, S. P.
    Hoimes, C. J.
    Zakharia, Y.
    Milowsky, M. I.
    Kilari, D.
    Shah, S. A.
    Davis, N. B.
    Emamekhoo, H.
    Gupta, S.
    Bellmunt, J.
    Grivas, P.
    Campbell, M. T.
    Alva, A.
    Koshkin, V. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1219 - S1219
  • [35] Analysis of a cohort of elderly patients (p) with head and neck cancer (HNC) managed within a multidisciplinary head and neck cancer unit (HNCU)
    Ferrando Diez, A.
    Viros Porcuna, D.
    Teruel Garcia, I.
    Planas Toledano, I.
    Garcia Linares, J.
    Cuadras Collsamata, P.
    Quer Pi-Sunyer, A.
    Vina Soria, C.
    Carrasco Lopez, C.
    Traboulsi Garet, T.
    Massuet Vilamajo, A.
    Palau Viarnes, M. D. M.
    Sendros Madrono, M. J.
    Hernandez Vergara, P.
    Vila Poyatos, J.
    Bordonaba Leiva, S.
    Puyalto de Pablo, P.
    Perez Gomez, J. A.
    Cirauqui Cirauqui, B.
    Pollan Guisasola, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S672 - S672
  • [36] The prognostic value of FMISO and FDG PET in locally advanced head and neck cancer (HNC).
    Dirix, P.
    Plessers, L.
    Slagmolen, P.
    Stroobants, S.
    Van den Bogaert, W.
    RADIOTHERAPY AND ONCOLOGY, 2007, 82 : S41 - S41
  • [37] Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy
    Gurney, Howard
    Mamtani, Ronac
    Rosenberg, Jonathan E.
    Powles, Thomas
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Bedke, Jens
    van der Heijden, Michiel
    Wu Chunzhang
    Hepp, Zsolt
    McKay, Caroline
    Petrylak, Daniel P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 66 - 67
  • [38] Prospective assessment of diurnal variation of Xerostomia in treated head neck cancer (HNC) patients
    Agarwal, S.
    Doshi, A.
    Patel, R.
    Roy, M.
    Kalyani, N.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S954 - S955
  • [39] EV-301 Long-Term Outcomes: 24-Month Findings From Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy in Previously Treated Advanced Urothelial Carcinoma
    Rosenberg, J.
    Powles, T.
    Sonpavde, G.
    Loriot, Y.
    Duran, I.
    Lee, J.
    Matsubara, N.
    Vulsteke, C.
    Castellano, D.
    Mamtani, R.
    Wu, C.
    Matsangou, M.
    Campbell, M.
    Petrylak, D.
    Cathomas, R.
    SWISS MEDICAL WEEKLY, 2022, 152 : 16S - 17S
  • [40] Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
    Vlachou, Evangelia
    Elias, Roy
    Hahn, Noah M.
    Mcconkey, David James
    Johnson, Burles Avner
    Hoffman-Censits, Jean H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 570 - 570
12345